JP5246903B2 - β−アミノカルボニル化合物の製法 - Google Patents
β−アミノカルボニル化合物の製法 Download PDFInfo
- Publication number
- JP5246903B2 JP5246903B2 JP2012522566A JP2012522566A JP5246903B2 JP 5246903 B2 JP5246903 B2 JP 5246903B2 JP 2012522566 A JP2012522566 A JP 2012522566A JP 2012522566 A JP2012522566 A JP 2012522566A JP 5246903 B2 JP5246903 B2 JP 5246903B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- binol
- reaction
- brs
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/60—Preparation of compounds containing amino groups bound to a carbon skeleton by condensation or addition reactions, e.g. Mannich reaction, addition of ammonia or amines to alkenes or to alkynes or addition of compounds containing an active hydrogen atom to Schiff's bases, quinone imines, or aziranes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/04—Formation of amino groups in compounds containing carboxyl groups
- C07C227/10—Formation of amino groups in compounds containing carboxyl groups with simultaneously increasing the number of carbon atoms in the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
窒素置換したシュレンク反応容器に、硫酸マグネシウム100mgを加えて、減圧下(<5Torr)、ヒートガンで3〜5分程度加熱乾燥した。その反応容器を減圧のまま室温まで放熱し、窒素導入した。その後、その反応容器に(R)−BINOL(7.1mg,0.025mmol)、トルエン(3mL)を加え、よく撹拌した。この混合液を−20℃に冷却し、n−Bu2Mg(1.0Mヘプタン溶液、25.0μL、0.025mmol)を加え、−20℃で5分間撹拌した。次いで、マロン酸ジメチル(62.9μL,0.55mmol)を加え、−20℃で5分間撹拌した。最後に、アルジミンとしてtert−ブチルベンジリデンカーバメート(102.6mg,0.50mmol)を加えて、−20℃で3時間撹拌した。反応終了をTLCで確認し、1M塩化水素−メタノール溶液(2mL)を加えて反応を停止した。反応混液に酢酸エチル(10mL)と水(5mL)を加え、通常の分液処理を行った。水層からさらに酢酸エチル抽出(10mL×2回)を行った。抽出した有機層は飽和塩化ナトリウム水溶液(10mL)で洗浄し、硫酸ナトリウムで乾燥後、ろ過、濃縮した。濃縮物をシリカゲルカラムクロマトグラフィー(ヘキサン:酢酸エチル=5:1〜2:1)に展開して生成物を分取し、純生成物を収率>99%(169mg)で得た。更に、キラルカラムAD−Hを充填した高速液体クロマトグラフィー(ヘキサン:イソプロパノール=9:1,1.0mL/min)により、生成物の鏡像体過剰率を92%ee(R)と決定した。この実施例1では、(R)−BINOLとn−Bu2Mgの両方とも、アルジミンに対して5mol%使用した。
マロン酸ジメチルと表1に示す各種のアルジミン類との不斉マンニッヒ型反応を、実施例1と同様にして行った。その結果を表1に示す。実施例2〜9のいずれにおいても、非常に高い鏡像体過剰率で生成物が得られた。なお、実施例5の収率及び鏡像体過剰率の欄の[ ]内の数値は、5mol%の(R)−BINOLと7.5mol%のn−Bu2Mgを用いた場合の結果を示す。実施例5では、5mol%の(R)−BINOLと5mol%のn−Bu2Mgを用いた場合に比べて、5mol%の(R)−BINOLと7.5mol%のn−Bu2Mgを用いた場合の方が好結果となった。その理由は、前者ではアルジミンのメトキシ基の酸素原子にマグネシウムがキレートして触媒種が減少したのに対し、後者ではn−Bu2Mgを増量したことによりそのような触媒種の減少を防止できたためと考えられる。この結果から、アルジミンの構造によっては、(R)−BINOLの使用量よりもn−Bu2Mgの使用量を多くすることが好ましいことがあることがわかった。
1H NMR (400 MHz, CDCl3) δ 1.42 (s, 9H), 3.64 (s, 3H), 3.75 (s, 3H), 3.93 (brs,1H), 5.49 (brs, 1H), 6.16 (brs, 1H), 7.23-7.34 (m, 5H). 13C NMR (100 MHz, CDCl3) δ 28.2 (3C), 52.5, 52.8, 53.3, 56.6, 79.7, 126.1 (2C), 127.6, 128.6 (2C), 139.3, 155.1, 167.5, 168.3. M.p. 95-97℃. IR (KBr) 3375, 2982, 2954, 1737, 1689, 1521, 1294, 1245, 1173, 1011, 705 cm-1. [α]D 27 = -14.8 (c 1.0, CHCl3, 92% ee(R)) HRMS (FAB+) calcd for C17H23NNaO6 [M+Na]+ 360.1423, found 360.1419. HPLC analysis; AD-H, n-hexane/i-PrOH = 9/1, 1.0 mL/min, tR = 21.4 min (minor, S), 29.0 min (major, R).
1H NMR (400 MHz, CDCl3) δ 3.61 (s, 3H), 3.68 (s, 3H), 3.93 (brs, 1H), 5.07 (d, J = 12.0 Hz, 1H), 5.11 (d, J = 12.0 Hz, 1H), 5.55 (brs, 1H), 6.45 (brs, 1H), 7.10-7.55 (m, 10H). 13C NMR (100 MHz, CDCl3) δ 52.7, 53.0, 54.0, 56.6, 67.0, 126.3 (2C), 127.9, 128.1 (2C), 128.1 (2C), 128.5 (2C), 128.8, 128.8 (2C), 136.4, 139.1, 155.8, 167.4, 168.4. IR (neat) 3335, 4954, 1736, 1507, 1240, 1162, 1044 cm-1. [α]D 24 = +9.6 (c 1.0, CHCl3, 82% ee (R)) HRMS (FAB+) calcd for C20H21NNaO6 [M+Na]+ 394.1267, found 394.1261. HPLC analysis; AD-H, n-hexane/i-PrOH = 9/1, 1.0 mL/min, tR = 46.8 min (minor, S), 67.0 min (major, R).
1H NMR (400 MHz, CDCl3) δ 1.41 (s, 9H), 3.65 (s, 3H), 3.75 (s, 3H), 3.88 (brs, 1H), 5.44 (brs, 1H), 6.16 (brs, 1H), 7.24 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.4 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 28.2 (3C), 52.6, 52.7, 53.1, 56.5, 80.1, 127.7 (2C), 128.8 (2C), 133.6, 138.1, 155.1, 167.4, 168.3. IR (neat) 3421, 2978, 1717, 1491, 1244, 1161 cm-1. [α]D 23 = -10.0 (c 1.00, CHCl3, 93% ee (R)) HRMS (FAB+) calcd for C17H22ClNNaO6 [M+Na]+ 394.1033, found 394.1042. HPLC analysis; AD-H, n-hexane/i-PrOH = 9/1, 1.0 mL/min, tR = 28.5 min (major, R), 35.6 min(minor, S).
1H NMR (400 MHz, CDCl3) δ 1.42 (s, 9H), 2.33 (s, 3H), 3.64 (s, 3H), 3.74 (s, 3H), 3.91 (brs, 1H), 5.45 (brs, 1H), 6.14 (brs, 1H), 7.02-7.13 (m, 3H), 7.20 (t,J = 7.2 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 21.6, 28.4 (3C), 52.6, 53.0, 53.4, 56.8, 79.8, 123.2, 127.0, 128.5, 128.6, 138.3, 139.4, 155.2, 167.7, 168.5. IR (neat) 3428, 2977, 1718, 1497, 1366, 1243, 1164, 1046 cm-1. [α]D 24 = -14.0 (c 1.00, CHCl3, 87% ee (R)). HRMS (FAB+) calcd for C18H25NNaO6 [M+Na]+ 374.1580,found 374.1574. HPLC analysis; AD-H, n-hexane/i-PrOH = 9/1, 1.0 mL/min, tR = 17.9 min (minor, S), 25.8 min (major, R).
1H NMR (400 MHz, CDCl3) δ 1.41 (s, 9H), 3.65 (s, 3H), 3.74 (s, 3H), 3.83 (s, 3H), 3.86 (s, 3H), 3.88 (brs, 1H), 5.40 (brs, 1H), 6.10 (brs, 1H), 6.75-6.86 (m,3H). 13C NMR (100 MHz, CDCl3) δ 28.2 (3C), 52.7, 52.9, 53.3, 55.9, 56.0, 56.8, 79.8. 109.6, 111.1, 118.3, 132.1, 148.4, 148.9, 155.2, 167.6, 168.6. M.p. 96-97 °C. IR (KBr) 3373, 2976, 1717, 1517, 1259, 1163, 1026 cm-1. [α]D 23 = -2.4 (c 1.0, CHCl3, 90% ee (R)). HRMS (FAB+) calcd for C19H27NNaO8 [M+Na]+ 420.1634, found 420.1622. HPLC analysis; AD-H, n-hexane/i-PrOH = 4/1, 1.0 mL/min, tR =23.1 min (minor, S), 26.4 min (major, R).
1H NMR (400 MHz, CDCl3) δ 1.44 (s, 9H), 3.72 (s, 3H), 3.75 (s, 3H), 4.05 (brs, 1H), 5.54 (brs, 1H), 5.92 (brs, 1H), 6.22 (m, 1H), 6.30 (m, 1H), 7.31 (m, 1H).13C NMR (100 MHz, CDCl3) δ 28.3 (3C), 48.4, 52.7, 53.0, 54.1, 80.1, 106.8, 110.6, 142.1, 152.2, 155.1, 167.4, 168.3. IR (neat) 3428, 2978, 1719, 1497, 1367, 1248, 1165 cm-1. [α]D 24 = -3.6 (c 1.00, CHCl3, 90% ee (R)) HRMS (FAB+) calcd for C15H21NNaO7 [M+Na]+ 350.1216, found 350.1209. HPLC analysis; AD-H, n-hexane/i-PrOH = 9/1, 1.0 mL/min, tR = 14.0 min (minor, S), 23.8 min (major, R).
1H NMR (400 MHz, CDCl3) δ 1.43 (s, 9H), 3.68 (s, 3H), 3.75 (s, 3H), 3.96 (brs, 1H), 5.55 (brs, 1H), 6.07 (brs, 1H), 7.00 (dd, J = 5.1, 1.2 Hz, 1H), 7.14 (dd,J = 3.0, 1.2 Hz, 1H), 7.28 (dd, J = 5.1, 3.0 Hz, 1H). 13C NMR (100 MHz, CDCl3)δ 28.3 (3C), 50.0, 52.6, 52.9, 56.1, 79.8, 121.5, 126.0, 126.4, 140.7, 155.1,167.5, 168.5. IR (neat) 3423, 2977, 1736, 1498, 1366, 1245, 1165, 1046 cm-1. [α]D 24 = -3.6 (c 1.00, CHCl3, 95% ee (R)). HRMS (FAB+) calcd for C15H21NNaO6S [M+Na]+ 366.0987, found 366.0979. HPLC analysis; AD-H, n-hexane/i-PrOH = 9/1, 1.0 mL/min, tR = 29.5 min (minor, S), 33.9 min (major, R).
1H NMR (400 MHz, CDCl3) δ 1.43 (s, 9H), 3.67 (s, 3H), 3.77 (s, 3H), 3.95 (brs, 1H), 5.53 (brs, 1H), 6.23 (brs, 1H), 7.28 (dd, J = 7.8, 4.8 Hz, 1H), 7.68 (dd,J = 7.8, 1.8 Hz, 1H), 8.53 (dd, J = 4.8, 1.8 Hz, 1H), 8.59 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 28.3 (3C), 51.6, 52.8, 53.1, 56.2, 80.3, 123.4, 134.2, 135.1,148.2, 149.1, 155.1, 167.2, 168.1. IR (neat) 3368, 2978, 1740, 1507, 1434, 1273, 1165, 1025 cm-1. [α]D 24 = -8.8 (c 1.00, CHCl3, 89% ee (R)). HRMS (FAB+) calcd for C16H22N2NaO6 [M+Na]+ 361.1376, found 361.1381. HPLC analysis; AD-H, n-hexane/i-PrOH = 4/1, 1.0 mL/min, tR = 18.7 min (minor, R), 25.0 min (major, S).
1H NMR (400 MHz, CDCl3) δ 1.42 (s, 9H), 3.55 (s, 3H), 3.82 (s, 3H), 4.09 (brs, 1H), 6.30 (brs, 1H), 6.60 (brs, 1H), 7.42 (t, J = 7.8 Hz, 1H), 7.50 (m, 2H), 7.58 (t, J = 6.9 Hz, 1H), 7.77 (d, J = 7.8 Hz, 1H), 7.87 (d, J = 7.8 Hz, 1H), 8.11 (d, J = 8.7 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 28.4 (3C), 50.2, 52.5, 53.2, 55.4, 79.9, 122.2, 123.7, 125.2, 125.9, 126.9, 128.6, 129.2, 130.1, 133.9, 134.8, 155.2, 167.9, 168.7. IR (neat) 3421, 2977, 1717, 1496, 1366, 1245, 1163, 1055 cm-1. [α]D 23 = -34.4 (c 1.00, CHCl3, 88% ee (R)). HRMS (FAB+) calcd for C21H25NNaO6 [M+Na]+ 410.1580, found 410.1584. HPLC analysis; AD-H, n-hexane/i-PrOH = 9/1, 1.0 mL/min, tR = 14.5 min (major, R), 17.1 min (minor, S).
tert−ブチルベンジリデンカーバメートと表2に示す各種のマロン酸ジエステル類との不斉マンニッヒ型反応を、実施例1と同様にして行った。その結果を表2に示す。実施例10〜14のいずれにおいても、非常に高い収率、鏡像体過剰率で生成物が得られた。また、実施例14の収率及び鏡像体過剰率の欄の[ ]内の数値は、2.5mol%の(R)−BINOLと3.75mol%のn−Bu2Mgを用いた場合の結果を示す。
1H NMR (400 MHz, CDCl3) δ 0.79 (t, J = 7.2 Hz, 3H), 0.92 (t, J = 7.2 Hz, 3H),1.40 (s, 9H), 1.52 (m, 2H), 1.66 (m, 2H), 3.91 (brs, 1H), 3.99 (m, 2H), 4.10 (m, 2H), 5.49 (brs, 1H), 6.21 (brs, 1H), 7.20-7.34 (m, 5H). 13C NMR (100 MHz, CDCl3) δ 10.2, 10.3, 21.7, 21.9, 28.3 (3C), 53.5, 57.0, 67.2, 67.6, 79.7, 126.3 (2C), 127.6, 128.6 (2C), 139.7, 155.1, 167.3, 168.3. IR (neat) 3430, 2971, 1724,1497, 1365, 1249, 1167, 1057 cm-1. [α]D 24 = -8.8 (c 1.0, CHCl3, 92% ee (R)). HRMS (FAB+) calcd for C21H31NNaO6 [M+Na]+ 416.2049, found 416.2062. HPLC analysis; AD-H, n-hexane/i-PrOH = 9/1, 1.0 mL/min, tR = 14.3 min (minor, S), 19.2 min(major, R).
1H NMR (400 MHz, CDCl3) δ 1.41 (s, 9H), 4.01 (brs, 1H), 5.04 (s, 2H), 5.12 (d, J = 12.0 Hz, 1H), 5.17 (d, J = 12.0 Hz, 1H), 5.56 (brs, 1H), 6.20 (brs, 1H), 7.06-7.12 (m, 2H), 7.20-7.36 (m, 13H). 13C NMR (100 MHz, CDCl3) δ 28.4 (3C), 53.4, 56.8, 67.3, 67.6, 79.7, 126.2 (2C), 127.6, 128.0, 128.2 (2C), 128.3, 128.4, 128.5 (2C), 128.6 (4C), 134.8, 134.9, 139.2, 139.3, 155.0, 166.8, 167.8. M.p. 105-106 °C. IR (KBr) 3429, 2977, 1720, 1496, 1366, 1251, 1163, 1026 cm-1. [α]D 22 = -15.2 (c 1.00, CHCl3, 91% ee (R)) HRMS (FAB+) calcd for C29H31NNaO6 [M+Na]+ 512.2049, found 512.2055. HPLC analysis; AS-H, n-hexane/i-PrOH = 39/1, 1.0 mL/min, tR = 28.1 min (major, R), 36.6 min (minor, S).
1H NMR (400 MHz, CDCl3) δ 1.41 (s, 9H), 3.97 (s, 1H), 4.53 (m, 2H), 4.64 (m, 2H), 5.15 (d, J = 16.2 Hz, 1H), 5.16 (d, J = 10.8 Hz, 1H), 5.24 (d, J = 10.8 Hz,1H), 5.32 (d, J = 16.2 Hz, 1H), 5.53 (brs, 1H), 5.74 (m, 1H), 5.88 (m, 1H), 6.20 (brs, 1H), 7.21-7.36 (m, 5H). 13C NMR (100 MHz, CDCl3) δ 28.4 (3C), 53.5, 57.0, 66.2, 66.6, 79.8, 118.8, 119.1, 126.3 (2C), 127.6, 128.7 (2C), 131.2, 131.3, 139.4, 155.1, 166.8, 167.7. IR (neat) 3429, 2978, 1720, 1496, 1367, 1249, 1165 cm-1. [α]D 25 = -8.0 (c 0.5, CHCl3, 88% ee (R)) HRMS (FAB+) calcd for C21H27NNaO6 [M+Na]+ 412.1736, found 412.1737. HPLC analysis; AD-H, n-hexane/i-PrOH = 9/1, 1.0 mL/min, tR = 23.3 min (minor, S), 33.3 min (major, R).
1H NMR (400 MHz, CDCl3) δ 1.41 (s, 9H), 3.77 (s, 3H), 3.80 (s, 3H), 5.68 (d,J = 9.9 Hz, 1H), 5.97 (d, J = 9.9 Hz, 1H), 7.28-7.44 (m, 5H). 13C NMR (100 MHz, CDCl3) δ 28.3 (3C), 54.0, 54.1, 58.8, 73.4, 80.2, 128.2 (2C), 128.6, 128.8 (2C), 136.0, 154.3, 165.9, 166.1. IR (neat) 3439, 2978, 1719, 1494, 1367, 1255, 1166, 1022 cm-1. [α]D 23 = +3.2 (c 1.0, CHCl3, 97% ee (S)). HRMS (FAB+) calcd for C17H22ClNNaO6 [M+Na]+ 394.1033, found 394.1042. HPLC analysis; AD-H × 2, n-hexane/i-PrOH = 19/1, 0.5 mL/min, tR = 52.4 min (minor, R), 55.9 min (major, S).
1H NMR (400 MHz, CDCl3) δ 1.41 (s, 9H), 3.77 (s, 3H), 3.79 (s, 3H), 5.62 (d, J = 9.9 Hz, 1H), 6.16 (d, J = 9.9 Hz, 1H), 7.28-7.42 (m, 5H). 13C NMR (100 MHz,CDCl3) δ 28.3 (3C), 54.0, 54.2, 59.3, 64.4, 80.2, 128.2 (2C), 128.5, 128.9 (2C), 136.4, 154.4, 166.4, 166.7. IR (neat) 3439, 2978, 1715, 1317, 1245, 1165, 1037 cm-1. [α]D 24 = +24.8 (c 0.50, CHCl3, 96% ee (S)). HRMS (FAB+) calcd for C17H22BrNNaO6 [M+Na]+ 438.0528, found 438.0528. HPLC analysis; AD-H × 2, n-hexane/i-PrOH = 19/1, 0.5 mL/min, tR = 45.1 min (minor, R), 54.7 min (major, S).
実施例15では、下記式に示すように、窒素上に4−メトキシフェニル基を有するグリオキサール由来のアルジミンと、α位に臭素原子を有するマロン酸ジメチルとの不斉マンニッヒ型反応を、実施例1と同様にして行った。この場合も、下記式に示すように、比較的良好な結果が得られた。
tert−ブチルベンジリデンカーバメートとマロン酸ジメチルとの不斉マンニッヒ型反応を、(R)−BINOLと表3に示すMXとの存在下、表3に示す反応条件で実施例1に準じて行った。その結果を表3に示す。この表3から明らかなように、(R)−BINOLのみを用いた比較例1や(R)−BINOLとn−BuLiとを用いた比較例2,4、(R)−BINOLとn−BuLiとt−BuOHを用いた比較例3,5では、反応が進行するものもあったが、いずれも鏡像体過剰率が低かった。また、5mol%の(R)−BINOLと2.5mol%のn−Bu2Mgとを用いた比較例6(BINOL/Mgのモル比=1/0.5)では、ほとんど反応が進行しなかった。これに対して、5mol%の(R)−BINOLと5mol%のn−Bu2Mgとを用いた実施例16(BINOL/Mgのモル比=1/1)では、収率、鏡像体過剰率とも非常に高くなった。また、5mol%の(R)−BINOLと10mol%のn−Bu2Mgとを用いた実施例17(BINOL/Mgのモル比=1/2)では、実施例16と比べて収率は同等で、鏡像体過剰率はやや低下したものの十分高い値であった。
比較例7では、3,3’位に3,4,5−トリフルオロフェニル基を導入した(R)−BINOLとn−Bu2Mgとをそれぞれ2.5mol%用い、反応時間を2時間とした以外は、実施例1と同様にして反応を行った。そうしたところ、対応するβ−アミノカルボニル化合物はほとんど得られなかった。また、n−Bu2Mgを2倍つまり5mol%に増やし反応時間を5時間にしたところ、対応するβ−アミノカルボニル化合物は収率88%で得られたが、その鏡像体過剰率は35%eeに過ぎなかった。このことから、目的とする生成物を高い鏡像体過剰率で得るためには、(R)−BINOLの3,3’位の置換基は不要であることがわかった。
Claims (5)
- 光学活性なBINOLと、該BINOLに対して1〜2倍モルのジアルキルマグネシウム(2つのアルキル基は同じか又は異なる)との存在下、窒素が保護されたアルジミン類とマロン酸ジエステル類とのマンニッヒ型反応により、光学活性なβ−アミノカルボニル化合物を得る、β−アミノカルボニル化合物の製法。
- 前記アルジミン類は、R1−CH=NR2(R1はアリール基又はエステル基、R2はtert−ブトキシカルボニル(Boc)、ベンジルオキシカルボニル(Cbz)、2,2,2−トリクロロエトキシカルボニル(Troc)、フェニル基、2−メトキシフェニル基、4−メトキシフェニル基又はナフチル基)で表される化合物である、請求項1記載のβ−アミノカルボニル化合物の製法。
- 前記マロン酸ジエステル類は、CHX(CO2R3)2(Xは水素原子又はハロゲン原子、R3はアルキル、アリル、ベンジル又はアリール)で表される化合物である、請求項1又は2に記載のβ−アミノカルボニル化合物の製法。
- 前記BINOLは、前記アルジミン類に対して2.5〜10mol%使用する、請求項1〜3のいずれか1項に記載のβ−アミノカルボニル化合物の製法。
- 反応溶媒として、芳香族系溶媒又はハロゲン化炭化水素系溶媒を使用する、請求項1〜4のいずれか1項に記載のβ−アミノカルボニル化合物の製法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012522566A JP5246903B2 (ja) | 2010-07-01 | 2011-06-22 | β−アミノカルボニル化合物の製法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010150999 | 2010-07-01 | ||
JP2010150999 | 2010-07-01 | ||
PCT/JP2011/064220 WO2012002203A1 (ja) | 2010-07-01 | 2011-06-22 | β-アミノカルボニル化合物の製法 |
JP2012522566A JP5246903B2 (ja) | 2010-07-01 | 2011-06-22 | β−アミノカルボニル化合物の製法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP5246903B2 true JP5246903B2 (ja) | 2013-07-24 |
JPWO2012002203A1 JPWO2012002203A1 (ja) | 2013-08-22 |
Family
ID=45401923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012522566A Expired - Fee Related JP5246903B2 (ja) | 2010-07-01 | 2011-06-22 | β−アミノカルボニル化合物の製法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8507715B2 (ja) |
EP (1) | EP2657222B1 (ja) |
JP (1) | JP5246903B2 (ja) |
CN (1) | CN102958910B (ja) |
WO (1) | WO2012002203A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008163022A (ja) * | 2006-12-20 | 2008-07-17 | Brandeis Univ | シンコナアルカロイド触媒不斉マンニッヒ反応 |
JP2010207786A (ja) * | 2009-03-12 | 2010-09-24 | Japan Science & Technology Agency | アルカリ土類金属系触媒、及び反応方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4431821A1 (de) * | 1994-09-07 | 1996-03-14 | Bayer Ag | Verfahren zur Herstellung von N-Arylaminoacrylsäurederivaten und die Verwendung so hergestellter N-Arylaminoacrylsäurederivate zur Herstellung von 4-Chinolon-3-carbonsäurederivaten |
CN100410234C (zh) * | 2003-04-25 | 2008-08-13 | 东亚合成株式会社 | 利用手性布朗斯台德酸的不对称合成用催化剂和使用该催化剂的不对称合成方法 |
US8097750B2 (en) | 2006-12-20 | 2012-01-17 | Brandeis University | Cinchona alkaloid-catalyzed asymmetric mannich reactions |
US20100249431A1 (en) * | 2007-10-24 | 2010-09-30 | National University Corporation Nagoya University | Process for manufacturing disulfonic acid compound, asymmetric mannich catalst, process for manufacturing beta-aminocarbonyl derivative, and novel disulfonate |
-
2011
- 2011-06-22 US US13/700,746 patent/US8507715B2/en not_active Expired - Fee Related
- 2011-06-22 JP JP2012522566A patent/JP5246903B2/ja not_active Expired - Fee Related
- 2011-06-22 EP EP11800668.3A patent/EP2657222B1/en not_active Not-in-force
- 2011-06-22 CN CN201180028613.0A patent/CN102958910B/zh not_active Expired - Fee Related
- 2011-06-22 WO PCT/JP2011/064220 patent/WO2012002203A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008163022A (ja) * | 2006-12-20 | 2008-07-17 | Brandeis Univ | シンコナアルカロイド触媒不斉マンニッヒ反応 |
JP2010207786A (ja) * | 2009-03-12 | 2010-09-24 | Japan Science & Technology Agency | アルカリ土類金属系触媒、及び反応方法 |
Non-Patent Citations (1)
Title |
---|
JPN7013000808; KOBAYASHI, S. et al.: Chem. Asian J. 5, 2010, p.493-495 * |
Also Published As
Publication number | Publication date |
---|---|
US8507715B2 (en) | 2013-08-13 |
CN102958910B (zh) | 2014-03-12 |
EP2657222A1 (en) | 2013-10-30 |
WO2012002203A1 (ja) | 2012-01-05 |
US20130079543A1 (en) | 2013-03-28 |
CN102958910A (zh) | 2013-03-06 |
JPWO2012002203A1 (ja) | 2013-08-22 |
EP2657222B1 (en) | 2014-10-01 |
EP2657222A4 (en) | 2014-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shaw et al. | Directed carbonylative (3+ 1+ 2) cycloadditions of amino-substituted cyclopropanes and alkynes: reaction development and increased efficiencies using a cationic rhodium system | |
Lu et al. | Dipeptide-derived multifunctional phosphonium salt as a catalyst to synthesize highly functionalized chiral cyclopentanes | |
Yan et al. | Asymmetric aldol reactions catalyzed by efficient and recyclable silica‐supported proline‐based peptides | |
CN111925356B (zh) | 手性喹啉-咪唑啉配体的合成方法及其应用 | |
Han et al. | Chiral ferrocenyl P, S-ligands for highly efficient copper-catalyzed asymmetric [3+ 2] cycloaddition of azomethine ylides | |
JP5246903B2 (ja) | β−アミノカルボニル化合物の製法 | |
EP1619179A1 (en) | Production method of O-substituted tyrosine compound | |
JP2012082155A (ja) | トリアゾリウム塩及びその製造方法、アジドアルコール並びに不斉反応によるアルキル化オキシインドールの製造方法 | |
Xu et al. | Highly enantioselective addition of methyl propiolate to aldehydes catalyzed by a titanium (IV) complex of a β-hydroxy amide | |
WO2016133217A1 (ja) | 光学活性オキシインドール化合物の製造方法及びそれに触媒として用いられるトリアゾリウム塩 | |
JP5408662B2 (ja) | ジスルホン酸化合物の製法、不斉マンニッヒ触媒、β−アミノカルボニル誘導体の製法及び新規なジスルホン酸塩 | |
JP2011051904A (ja) | 第3級アルコールの製造方法 | |
CN113024585B (zh) | 合成具有季碳手性中心的α-氨基酸酯类化合物的方法 | |
JP6235783B2 (ja) | 不斉アザディールス−アルダー反応用触媒、それを用いた光学活性テトラヒドロピリジン化合物の製造方法 | |
US10889599B2 (en) | 1,1-diborylalkyl-1-metal compounds, preparation method thereof, and their applications toward synthesis of 1,1-diboronate ester compounds | |
JP2004196710A (ja) | 配位子及び不斉触媒 | |
CN107325025A (zh) | 一种手性α‑氨基酸衍生物及其制备方法 | |
JP4759722B2 (ja) | 置換基を有する芳香族カルボン酸エステルの製造方法 | |
JP2008069104A (ja) | ヘリセン誘導体、トリイン誘導体、ヘリセン誘導体の製造方法 | |
WO2016056669A1 (ja) | 固相担持ルテニウム-ジアミン錯体及び光学活性化合物の製造方法 | |
JP2006151839A (ja) | α,β−不飽和カルボン酸誘導体からのエナンチオ選択的β−シアノカルボン酸誘導体の調製方法、及び該方法に用いる触媒 | |
CN116514698A (zh) | 一种沃诺拉赞中间体的制备方法及其应用 | |
KR100927242B1 (ko) | 알릴알렌 유도체와 이의 제조방법 | |
ファン,ティハンガー | Development of Novel Efficient Palladium-Catalyzed Carbonylation Reactions in Combination with Copper Salts | |
WO2010098193A1 (ja) | β-アミノカルボニル化合物の製法及びリチウムビナフトラート錯体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130312 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5246903 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160419 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |